検索
Immix Biopharma Inc
IMMXウォッチリストに追加
10.340USD
+0.510+5.19%
終値 07/02, 13:00（ET）15分遅れの株価
547.51M時価総額
損失額直近12ヶ月PER
詳細情報 Immix Biopharma Inc 企業名
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Incの企業情報
企業コードIMMX
会社名Immix Biopharma Inc
上場日Dec 16, 2021
最高経営責任者「CEO」Rachman (Ilya)
従業員数18
証券種類Ordinary Share
決算期末Dec 16
本社所在地11400 West Olympic Blvd.
都市LOS ANGELES
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号90064
電話番号18889581084
ウェブサイトhttps://immixbio.com/
企業コードIMMX
上場日Dec 16, 2021
最高経営責任者「CEO」Rachman (Ilya)
Immix Biopharma Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
よくある質問
Immix Biopharma Incの上位5名の株主は誰ですか？
Immix Biopharma Incの上位5名の株主は以下のとおりです。Mr. Jason Hsu, Ph.D.
Immix Biopharma Inc（IMMX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Immix Biopharma Incの株式を保有している機関は105社あり、保有株式の総市場価値は約24.89Mで、全体の45.75%を占めています。2025Q4と比較して、機関の持ち株は18028804.00増加しています。